We are live on ! Find out more
MAM

MPM Asset Management Portfolio holdings

AUM $44.5M Turnover 20%
1-Year Est. Return 47.28%
This Fund
S&P 500
This Quarter Est. Return
-39.31%
1 Year Est. Return
-47.28%
3 Year Est. Return
+5.89%
5 Year Est. Return
-18.52%
10 Year Est. Return
+3.53%
AUM
$323M
AUM Growth
-$238M
Cap. Flow
+$12.6M
Cap. Flow %
3.91%
Top 10 Hldgs %
99.66%
Holding
17
New
2
Increased
–
Reduced
–
Closed
2
Avg Time Held
1.5 years
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1.5 years

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$27.3M
2
ELGX
Endologix Inc
ELGX
+$9.24M

Top Sells

Rank Stock Value
1
ALT icon
Altimmune
ALT
+$12.1M
2
TRIV
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RDUS icon
1
DELISTED
Radius Health, Inc.
RDUS
$183M 56.81%
5,831,253
– –
2014 Q2
7 quarters
CHMA
2
DELISTED
Chiasma, Inc. Common Stock
CHMA
$52M 16.13%
5,681,544
– –
2015 Q3
2 quarters
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.21B
$28.9M 8.95%
+2,168,691
New +$27.3M
2016 Q1
0 quarters
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$21M 6.5%
1,729,674
– –
2013 Q2
11 quarters
ELGX
5
DELISTED
Endologix Inc
ELGX
$9.38M 2.91%
+112,145
New +$9.24M
2016 Q1
0 quarters
NVRO icon
6
DELISTED
NEVRO CORP.
NVRO
$8.44M 2.62%
150,000
– –
2014 Q4
5 quarters
TARA icon
7
Protara Therapeutics
TARA
$144M
$7.61M 2.36%
24,585
– –
2014 Q4
5 quarters
PETX
8
DELISTED
Aratana Therapeutics, Inc.
PETX
$6.17M 1.91%
1,117,875
– –
2013 Q2
11 quarters
HSTO
9
DELISTED
Histogen Inc. Common Stock
HSTO
$2.55M 0.79%
5,960
– –
2013 Q3
10 quarters
AVTX icon
10
Avalo Therapeutics
AVTX
$652M
$2.22M 0.69%
207
– –
2015 Q4
1 quarter
SVRA icon
11
Savara
SVRA
$976M
$689K 0.21%
36,455
– –
2014 Q1
8 quarters
SGMO icon
12
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$136K 0.04%
22,487
– –
2013 Q4
9 quarters
CLCD
13
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$135K 0.04%
21,806
– –
2015 Q2
3 quarters
ETRM
14
DELISTED
EnteroMedics Inc.
ETRM
$72K 0.02%
1,060
– –
2013 Q2
11 quarters
MGNX icon
15
MacroGenics
MGNX
$211M
$59K 0.02%
3,168
– –
2013 Q4
9 quarters
ALT icon
16
Altimmune
ALT
$449M
– –
-21,159
Closed -$12.1M –
TRIV
17
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
– –
-1,776,692
Closed -$11.8M –

Similar funds

WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

MPM Asset Management's Q1 2016 Portfolio in Review

As of Q1 2016, MPM Asset Management held 17 positions worth $323M, down 42% from $560M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

MPM Asset Management deployed $12.6M of net new capital in Q1 2016, opening 2 new positions. Its largest new stake was Syndax Pharmaceuticals: 2,168,691 shares worth $28.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

On the sell side, the most notable exit was Altimmune, an estimated $12.1M sold.

  • MPM Asset Management's largest Q1 2016 buy was Syndax Pharmaceuticals: 2,168,691 shares worth $28.9M.
  • MPM Asset Management fully exited Altimmune in Q1 2016, selling an estimated $12.1M.
  • MPM Asset Management's ten largest holdings make up 100% of its $323M portfolio in Q1 2016.
  • MPM Asset Management opened 2 new positions and closed 2 in Q1 2016.
  • MPM Asset Management's portfolio value fell 42% quarter-over-quarter to $323M.

Based on MPM Asset Management's 13F filing for Q1 2016, filed 11 May 2016.